AbbVie’s Orilissa snagged its first FDA approval over the summer, and now it’s looking to make it two. On Wednesday, the Illinois drugmaker unveiled details from a pair of phase 3 studies showing that the drug had topped placebo at
read moreThe FDA Wednesday granted a Breakthrough Therapy Designation for Lilly’s Emgality for its ability to prevent cluster headaches, and the drugmaker now plans to file for approval in that use by the end of the year. More: Lilly's third-to-market Emgality nets
read moreAbbVie’s hepatitis C blockbuster Mavyret could soon also be an eight-week treatment for patients with compensated cirrhosis, down from the currently approved 12-week schedule, thanks to positive new phase 3b data. More: AbbVie's Mavyret shortens treatment period for some hep
read moreHere is some news of note for the week: PCI is adding to its Illinois plant; ADC gets funds for its Wales facility. More: News of Note—PCI and ADC Bio add to manufacturing; recalls up Source: fierce
read moreJust one day after Novartis laid out plans for the long-expected spinoff of its eye unit Alcon, the Swiss pharma giant found itself fending off a rumor that it also intends to wave goodbye to its generics business, Sandoz. More:
read moreMSD’s Keytruda has shown promise in a late-stage trial testing its safety and efficacy in patients with advanced or metastatic esophageal or esophagogastric junction carcinoma. More: MSD’s Keytruda shows benefit in oesophageal cancer trial Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals